Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Income from Continuing Operations (2016 - 2026)

Insight Molecular Diagnostics' Income from Continuing Operations history spans 6 years, with the latest figure at 23435000.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 30.31% to 23435000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 51124000.0, a 16.06% increase, with the full-year FY2025 number at 51124000.0, up 16.25% from a year prior.
  • Income from Continuing Operations hit 23435000.0 in Q4 2025 for Insight Molecular Diagnostics, down from 11048000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for IMDX hit a ceiling of 5959000.0 in Q1 2023 and a floor of 35691000.0 in Q4 2021.
  • Historically, Income from Continuing Operations has averaged 10969850.0 across 5 years, with a median of 9485500.0 in 2024.
  • The widest YoY moves for Income from Continuing Operations: up 274.6% in 2023, down 510.92% in 2023.
  • Tracing IMDX's Income from Continuing Operations over 5 years: stood at 35691000.0 in 2021, then surged by 66.33% to 12017000.0 in 2022, then tumbled by 33.08% to 15992000.0 in 2023, then crashed by 110.27% to 33627000.0 in 2024, then surged by 30.31% to 23435000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for IMDX at 23435000.0 in Q4 2025, 11048000.0 in Q3 2025, and 9842000.0 in Q2 2025.